Canadian Journal of Gastroenterology and Hepatology
Volume 2018 (2018), Article ID 4756147, 8 pages
https://doi.org/10.1155/2018/4756147

Review Article

Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery

Shuichiro Shiina,¹ Koki Sato,¹ Ryosuke Tateishi,² Motonori Shimizu,¹ Hideko Ohama,¹ Takeshi Hatanaka,¹ Masashi Takawa,¹ Hiroaki Nagamatsu,¹ and Yasuharu Imai¹

¹Department of Gastroenterology, Juntendo University School of Medicine, Japan
²Department of Gastroenterology, The University of Tokyo, Japan

Correspondence should be addressed to Shuichiro Shiina; ivo@juntendo.ac.jp

Received 31 December 2017; Revised 3 April 2018; Accepted 22 May 2018; Published 3 June 2018

Academic Editor: Tatsuo Kanda

Copyright © 2018 Shuichiro Shiina et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Image-guided percutaneous ablation is considered best in the treatment of early-stage hepatocellular carcinoma (HCC). Ablation is potentially curative, minimally invasive, and easily repeatable for recurrence. Ethanol injection used to be the standard in ablation. However, radiofrequency ablation has recently been the most prevailing ablation method for HCC. Many investigators have reported that radiofrequency ablation is superior to ethanol injection, from the viewpoints of treatment response, local tumor curativity, and overall survival. New-generation microwave ablation can create a larger ablation volume in a shorter time period. Further comparison studies are, however, mandatory between radiofrequency ablation and microwave ablation, especially in terms of complications and long-term survival. Irreversible electroporation, which is a non-thermal ablation method that delivers short electric pulses to induce cell death due to apoptosis, requires further studies, especially in terms of long-term outcomes. It is considerably difficult to compare outcomes in ablation with those in surgical resection. However, radiofrequency ablation seems to be a satisfactory alternative to resection for HCC 3 cm or smaller in Child-Pugh class A or B cirrhosis. Furthermore, radiofrequency ablation may be a first-line treatment in HCC 2 cm or smaller in Child-Pugh class A or B cirrhosis. Various innovations would further improve outcomes in ablation. Training programs may be effective in providing an excellent opportunity to understand basic concepts and learn cardinal skills for successful ablation. Sophisticated ablation would be more than an adequate alternative of surgery for small- and possibly middle-sized HCC.

1. Introduction

Hepatocellular carcinoma (HCC) is the sixth in prevalence and the second in mortality among malignant neoplasms in the world [1]. Currently, almost 80% of victims are found in Asia, and the global incidence of HCC is increasing steadily [2, 3]. Surgical resection can be applicable in only 20 % of HCC patients [4]. Furthermore, HCC frequently recurs even after apparently curative resection. Liver transplantation, which is the best therapeutic option in some patients because it can be a treatment not only for HCC but also for cirrhosis, plays a limited role by organ donor shortage. Thus, various nonsurgical therapies have developed [3, 5, 6]. Among these, image-guided percutaneous ablation is regarded as best in the treatment of early-stage HCC. It includes ethanol injection [7–9], microwave ablation (MWA) [10], radiofrequency ablation (RFA) [11–13], irreversible electroporation (IRE), and cryoablation. Ablation can be curative, minimally invasive, and easily repeatable for recurrence. Ablation is generally indicated on patients with small HCC, preferably for those with Child-Pugh class A or B liver dysfunction, up to three tumors each 3 cm or smaller in diameter [14, 15].

2. Ethanol Injection

Percutaneous ethanol injection was first described in the early 1980s [7–9] and had long been the standard in ablation. It is a well-tolerated, low-cost, and considerably safe treatment. Survival of patients who underwent ethanol injection has been reported to be 38–60% at 5 years [16–19]. In our study of 685 primary HCC patients on whom we performed 2,147 ethanol injection treatments, with a median follow-up of 51.6 months, survival rates were 49.0%, 17.9%, and 7.2% at 5, 10, and 20 years, respectively [19]. It has been reported that local tumor progression rates after percutaneous ethanol injection were 6–31%, which were significantly related to the size of tumor [16, 18, 20, 21]. There has been a general agreement that percutaneous ethanol injection is a safe procedure, with mortality and morbidity of 0–3.2% and 0–0.4%, respectively [18–20, 22]. Nowadays, ethanol injection is a treatment of choice only in cases in which RFA cannot be feasible because of either enterobiliary reflux, adhesion of the tumor with the gastrointestinal tract, or other reasons [15].

3. RFA

RFA uses high-frequency alternating current to destroy solid tumor tissue. Radiofrequency energy emitted from the exposed tip of the electrode is converted into heat. Heat is conducted considerably homogeneously in all directions; the capsule or septa of the lesion may not be a barrier of the conduction to a great degree. There are three types of electrodes: multitined expandable electrodes, internally cooled ones, and perfusion ones. RFA has recently been the most prevailing ablation technique for HCC [15]. It has been reported that survival at 5 years was 39.9–68.5% [14, 23–27]. In our study of 1,170 primary HCC patients on whom we performed 2,982 RFA treatments, with a median follow-up of 38.2 months, survival rates were 60.2 % and 27.3 % at 5 and 10 years, respectively [14]. It has been reported that local tumor progression rates after RFA were 2.4–27.0% [14, 23–27]. It has been reported that mortality and morbidity of RFA were 0.9–7.9% and 0–1.5%, respectively [14, 23–26]. Various clinical attempts, such as combination of transcatheter arterial chemoembolization followed by RFA [28] and hepatic arterial balloon occlusion during RFA [29], have been conducted to increase the ablation volume by decreasing the cooling effect of the arterial flow. There have also been some studies in which they say that multipolar RFA would be useful to increase the volume of ablation and reduce local tumor progression [30].

4. MWA

In MWA, tumor tissue is destroyed by direct hyperthermic injury produced by electromagnetic wave emitted from the noninsulated portions of the antenna. Microwave coagulation has been used in transaction of the liver to control bleeding from planes during resection. The first-generation MWA for clinical practice was reported in the 1990s [10]. However, its necrotic volume was small. It was prolate spheroid, 1.5 cm in short diameter and 2.5 cm in long diameter. Still worse, antenna shaft became hot from reflected power in the first-generation MWA, which results in development of pleural effusion or skin burn at the insertion site. We shifted from ethanol injection and the first-generation MWA to RFA in Japan [31].

MWA is, however, considered to have physical advantages in comparison with RFA. These advantages include a larger volume of active heating resulting in shorter procedure times, insensitivity to carbonization, higher tissue temperatures beyond the threshold of water vaporization, and less susceptibility to the heat sink effect of blood flow which results in incomplete ablation [32–34]. Thus, new-generation MWA systems incorporating water or gas antenna cooling and high-power generation have been developed and have recently been attracting large attention [35]. New-generation MWA may create a more predictable ablation zone and a larger ablation volume in a shorter time period. However, its clinical data have been insufficient compared with that of RFA. Further studies are mandatory especially in terms of long-term survival [36, 37].

5. IRE

IRE is a non-thermal ablation treatment that delivers short electric pulses to induce cell death due to apoptosis. The basic principle of IRE is to create irreversible pores in cellular bilipid membranes by subjecting them to a series of high voltage (>640 V/cm) and high intensity (>20 A) electrical pulses of short duration (70–100 μsec) [38]. With this method, the skeleton of connective tissue, vessels, and bile ducts are largely preserved [39]. IRE seems to be an attractive alternative option for tumors near the porta hepatis or others in which thermal ablations are risky to be performed [40, 41]. However, IRE is more invasive and troublesome because general anesthesia with muscular blockade is needed. In addition, IRE also produces some degree of thermal effects which can injure bile ducts and other structures. Further studies are mandatory in IRE especially in terms of long-term outcomes.

6. Cryoablation

In contrast to RFA and MWA, cryoablation uses extremely low temperature to kill tumors. Tumor tissue is destroyed by both direct and indirect effects. The direct effect is a result of intra-and extracellular ice crystal formation and solute-solvent shifts, which induce cell dehydration and rupture. The indirect effect resulted from the vascular injury which would result in ischemic hypoxia. Apoptosis and immunomodulation may also play a role in cell injury [42]. Cryoablation has an advantage of its precise monitoring of ablated area during the procedure by various imaging modalities, such as CT, MRI, or ultrasound [43], therefore optimally controlling the treatment effects. A meta-analysis concluded that RFA is superior to cryoablation from the viewpoints of complications, local recurrence of patient, and local recurrence of tumor although there was no significant difference in mortality [44]. However, a randomized controlled trial said that local tumor progression is significantly less frequent in cryoablation than in RFA, although complications, tumor-free survival rates, and overall survival rates were not significantly different between the two techniques [45].

7. Comparison among Percutaneous Ablation Therapies

Six randomized controlled trials have been reported to compare RFA with ethanol injection. Superiority of RFA to ethanol injection, from the viewpoints of treatment response, local tumor curativity, and overall survival, has been found in four of them [13, 46–48], while the other two trials showed that the overall survival was not significantly different between them [49]. Ethanol injection, however, does not need special instruments and is inexpensive [50]. Ethanol injection may be an option in very small HCC.

Regarding the first-generation MWA, a randomized controlled trial to compare it with RFA demonstrated that the number of treatment sessions was smaller in RFA, although there was no statistically significant difference in terms of complete therapeutic effect, major complication, and local tumor progression between them [51]. A cohort study to compare the first-generation MWA with RFA for HCC of up to 2 cm in diameter showed that RFA was more effective than the first-generation MWA, because there was a significant difference in terms of treatment sessions, size of necrotic area, local recurrence rate, cumulative survival rate, adverse events of pain, fever, biliary injury, pleural effusion, and ascites between the two therapies [52].

Regarding new-generation MWA, many studies failed to show that new-generation MWA is superior to RFA from the viewpoint of local control and overall survival. A cohort study to compare it with RFA showed that there was no significant difference in complete therapeutic response, residual foci of untreated disease rate, recurrence rate, or progression-free survival between the two therapies [53]. Another cohort study to compare new-generation MWA with RFA for HCC up to 5 cm in diameter showed that there was no significant difference in complete ablation, local tumor progression, overall survival, or disease-free survival rates [54]. Another study also failed to show that there was a significant difference in terms of complete ablation, local recurrence, major adverse events, disease-free survival, or overall survival rates between the two therapies [55]. Another study to compare the two therapies for HCC within the Milan criteria did not demonstrate that complete ablation, local recurrence, disease-free survival, cumulative survival, or major complication rates were different between them, either [56]. Another comparative study showed that there was no significant difference in complete ablation, complication, de novo lesions, portal vein thrombosis, abdominal lymphadenopathy, and overall survival rates between the two therapies, while local recurrence rates were significantly lower in MWA [57]. Further comparison studies are mandatory between RFA and new-generation MWA, especially in terms of adverse events and long-term survival.

8. Comparison between Percutaneous Ablation Therapies and Surgical Resection

Comparison of ablation with surgical resection is considerably difficult; the indications are somewhat different between the two treatments. Patients of multiple lesions, advanced age, or more deteriorated liver function tend to undergo ablation while those of a large tumor tend to receive surgical resection. Furthermore, both treatments are highly operator-dependent and their indications may be different from institution to institution. Thus, a patient who is decided by medical professionals to undergo ablation or surgical resection at an institution may not be given the same treatment at others.

There have been four randomized controlled trials to compare RFA with surgical resection. Three of them demonstrated that overall survival was not significantly different between the two treatments. A study on patients with a solitary HCC up to 5 cm in diameter showed that overall survival and disease-free survival were not statistically different between the two treatments, but adverse events were more frequent and severe in surgical resection [58]. Another study on patients with nodular diameters of less than 4 cm and one or two nodules showed that there were no significant differences between the two treatments in overall survival and recurrence-free survival [59]. In another trial on patients with HCC up to 3 cm in diameter, there was no significant difference of the disease-free and overall survival between the two treatments, although the postoperative adverse events were significantly more frequent and hospital stay was significantly longer in surgical resection [60]. Only the remaining study on patients within the Milan criteria showed that there was a significant difference in overall survival and recurrence-free survival between the two treatments [61]. There was a randomized controlled trial to compare chemoembolization plus RFA with partial hepatectomy for HCC within the Milan criteria, which said that partial hepatectomy had better overall and recurrence-free survival than the combination of chemoembolization with RFA [61, 62]. However, it does not seem to be widely used to combine chemoembolization with RFA for HCC within the Milan criteria.

Concerning overall survival, some nonrandomized comparative studies reported that RFA had similar outcomes to resection [63–76] while others found that resection had better survival [74, 77–82]. There was a study in which RFA showed a better long-term survival than surgical resection after propensity score analysis [83]. There was another study which reported that, in HCC cases of 2 cm or smaller, major adverse events occurred significantly more often in surgical resection than in RFA and overall survival was better in RFA than in surgical resection [84]. Even in studies in which surgical resection was reported to be superior to RFA, there were no significant differences in overall survival between the two treatments in patients with HCC 2 cm or smaller [80] or 3 cm or smaller in diameter [74, 78, 79]. RFA was associated with less frequent adverse events [71, 79] and shorter hospital stay [71]. From the viewpoint of cost-effectiveness, RFA may be superior to surgical resection [85]. RFA seems to be a satisfactory alternative to resection for HCC up to 3 cm in diameter in Child-Pugh class A or B cirrhosis. Furthermore, RFA may be a first-line treatment in HCC up to 2 cm in diameter in Child-Pugh class A or B cirrhosis.

Most studies reported that recurrence-free survival was better in surgical resection than in RFA, although overall survival was not significantly different between the two treatments. This is probably because surgical resection sacrifices a much larger volume of non-cancerous liver tissue. It may remove some latent metastases and reduce new carcinogenesis, resulting in lower recurrence rates. However, it may lead to liver decompensation in some cases. In addition, most recurrence can be treated curatively by iterative RFA but not by repeated surgical resection. In our study, the first recurrence was treated by iterative RFA in 659 (88.9 %) of the 741 patients. In the remaining, transarterial chemoembolization in 69 (9.3 %), systemic chemotherapy in 4 (0.5 %), surgical resection in 3 (0.4 %), radiation therapy in 2 (0.3 %), and supportive care in 4 (0.5 %) were chosen [14]. On the other hand, repeated surgical resection can be an option in only 20-30% of patients with recurrent HCC.

9. Various Innovations and Sophisticated Instruments

We developed a dedicated ultrasound transducer for puncture (PVT-350BTP, Toshiba, Japan) (Figure 1) in corporation with Toshiba. We have performed RFA over 10,000 cases of liver tumors using this dedicated ultrasound probe. Contrast-enhanced ultrasound is useful to detect viable tumor persistence following locoregional treatment (either ablation or chemoembolization). There are cases in which B-mode ultrasound cannot clearly identify a viable portion of the tumor. Using ultrasound contrast agents, vascular imaging shows a hypervascular area which represents the residual cancer tissue. We developed a dedicated procedure bed (Figure 2). Using this bed, we can keep a patient in an optimal position. Multimodality fusion imaging is also useful to detect tumors not clearly identified by ultrasound. It is a system in which fused CT or MR images created from previously acquired imaging data demonstrate the same plane and move synchronously with real-time ultrasound images. Various innovations would further improve outcomes in percutaneous ablation.

Figure 1: We participated in development of a dedicated ultrasonic transducer and have used it in 12,000 procedures of radiofrequency ablation. The dedicated ultrasonic transducer has the following advantages: (1) needle slot is located inside the transducer, (2) a puncture angle of 100 degrees is available in addition to 55, 70, and 85 degrees, (3) the same image is obtained as a regular convex transducer generates, (4) a puncture attachment is unified with the transducer, and (5) it is capable of multimodality fusion imaging.

Figure 2: We developed a dedicated procedure bed. Using this bed, we can keep a patient in an optimal position, such as right hemilateral decubitus position, left hemilateral decubitus position, head-up position, sitting position, and almost standing position.

10. Training Programs

Because ablation appears a simple procedure, it may be done without sufficient training. However, ablation is considerably operator-dependent. Its skills and outcomes differ much from operator to operator. In order to disseminate skills and know-hows, there are some training programs for ablation. For example, our training programs are composed of comprehensive lectures (Figure 3), live demonstrations (Figure 4), and case studies (Figure 5). We have held domestic training programs 10 times, and a total of 170 doctors attended. We also have had international ones 4 times, which were successfully completed with 49 participants in total. Training programs may be effective in providing an excellent opportunity to understand basic concepts and learn cardinal skills for successful ablation.

Figure 3: Lecture topics are current status of ablation, ablation systems, ultrasound systems, various techniques in ablation, and others.

Figure 4: In live demonstrations, we perform ablation on various cases: a case of first diagnosed cancer not difficult to ablate judging from its size and location, a case of a tumor beneath the diaphragm requiring artificial ascites, a case of a tumor in the caudate lobe, a case of a tumor adjacent to the heart, a case of a tumor next to portal vein or hepatic vein at porta hepatis, a case of a tumor over 5 cm in diameter, a case of more than five tumors, cases of hepatic metastasis from the colorectal cancer or the gastric cancer, a case of simple nodular type HCC with extranodular growth or confluent multinodular type HCC, a case of a tumor with unclear boundaries on ultrasound which requires contrast-enhanced ultrasound to perform RFA, a case in which a tumor cannot be detected on ultrasound and requires support of fusion imaging, and others. From these cases, we demonstrate the importance of appropriate patient posture, usefulness of our original dedicated probe for interventional procedures and our RFA dedicated operation table, and the way to carry out ablation under contrast-enhanced ultrasound guidance and with multimodality fusion imaging.

Figure 5: In case studies, difficult to ablate cases from participants’ institutions are presented and discussed.

11. Conclusions

Ablation has been widely performed in the treatment of HCC. Ablation is potentially curative, minimally invasive, and easily repeatable for recurrence. In RFA, outcomes in over 10-year period clearly show that RFA is a curative treatment and enables long-term survival. There are still arguments regarding whether it is proper to perform ablation on resectable cases or not. The number of patients treated by ablation, however, has been increasing. Various innovations would further improve outcomes in ablation. Training programs may be effective in acquiring necessary skills, knowledge, and experience for successful ablation. Sophisticated ablation would be more than an adequate alternative of surgery for small- and possibly middle-sized HCC.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

D. Maxwell Parkin, F. Bray, J. Ferlay, and P. Pisani, “Estimating the world cancer burden: Globocan 2000,” International Journal of Cancer, vol. 94, no. 2, pp. 153–156, 2001.

D. Poon, B. O. Anderson, L.-T. Chen et al., “Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009,” The Lancet Oncology, vol. 10, no. 11, pp. 1111–1118, 2009.

S. D. Ryder, “Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults,” Gut, vol. 52, no. 3, pp. iii1–iii8, 2003.

F. Borie, A.-M. Bouvier, A. Herrero et al., “Treatment and prognosis of hepatocellular carcinoma: A population based study in France,” Journal of Surgical Oncology, vol. 98, no. 7, pp. 505–509, 2008.

J. M. Llovet, A. Burroughs, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 362, no. 9399, pp. 1907–1917, 2003.

J. Bruix and M. Sherman, “Management of Hepatocellular carcinoma,” Hepatology, vol. 42, no. 5, pp. 1208–1236, 2005.

N. Sugiura, “Ultrasound image-guided percutaneous intratumor ethanol injection for small hepatocellular carcinoma,” Acta Hepatologica Japonica, pp. 24–920, 1983 (Japanese).

T. Livraghi, D. Festi, F. Monti, A. Salmi, and C. Vettori, “US-guided percutaneous alcohol injection of small hepatic and abdominal tumors,” Radiology, vol. 161, no. 2, pp. 309–312, 1986.

S. Shiina, H. Yasuda, H. Muto et al., “Percutaneous ethanol injection in the treatment of liver neoplasms.,” AJR. American journal of roentgenology, vol. 149, no. 5, pp. 949–952, 1987.

T. Seki, M. Wakabayashi, T. Nakagawa et al., “Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma,” Cancer, vol. 74, no. 3, pp. 817–825, 1994.

S. Rossi et al., “Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma,” Cancer J Sci Am, vol. 1, no. 1, pp. 73–81, 1995.

T. Livraghi, S. N. Goldberg, S. Lazzaroni, F. Meloni, L. Solbiati, and G. S. Gazelle, “Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection,” Radiology, vol. 210, no. 3, pp. 655–661, 1999.

S. Shiina, T. Teratani, S. Obi et al., “A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma,” Gastroenterology, vol. 129, no. 1, pp. 122–130, 2005.

S. Shiina, R. Tateishi, T. Arano et al., “Radiofrequency ablation for hepatocellular carcinoma: 10-Year outcome and prognostic factors,” American Journal of Gastroenterology, vol. 107, no. 4, pp. 569–577, 2012.

M. Omata, A.-L. Cheng, N. Kokudo et al., “Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update,” Hepatology International, vol. 11, no. 4, pp. 317–370, 2017.

M. Ebara, S. Okabe, K. Kita et al., “Percutaneous ethanol injection for small hepatocellular carcinoma: Therapeutic efficacy based on 20-year observation,” Journal of Hepatology, vol. 43, no. 3, pp. 458–464, 2005.

S. Shiina, K. Tagawa, Y. Niwa et al., “Percutaneous ethanol injection therapy for hepatocellular carcinoma: Results in 146 patients,” American Journal of Roentgenology, vol. 160, no. 5, pp. 1023–1028, 1993.

Y. M. Sung et al., “Long-term results of percutaneous ethanol injection for the treatment of hepatocellular carcinoma in Korea,” Korean J Radiol, vol. 7, no. 3, pp. 187–192, 2006.

S. Shiina, R. Tateishi, M. Imamura et al., “Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors,” Liver International, vol. 32, no. 9, pp. 1434–1442, 2012.

T. Livraghi, A. Giorgio, G. Marin et al., “Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection,” Radiology, vol. 197, no. 1, pp. 101–108, 1995.

H. Ishii, Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection, vol. 77, Cancer, 1996.

M. Di Stasi, L. Buscarini, T. Livraghi et al., “Percutaneous ethanol injection in the treatment of hepatocellular carcinoma: A multicenter survey of evaluation practices and complication rates,” Scandinavian Journal of Gastroenterology, vol. 32, no. 11, pp. 1168–1173, 1997.

R. Lencioni, D. Cioni, L. Crocetti et al., “Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation,” Radiology, vol. 234, no. 3, pp. 961–967, 2005.

R. Tateishi, S. Shiina, T. Teratani et al., “Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases,” Cancer, vol. 103, no. 6, pp. 1201–1209, 2005.

T. Livraghi, F. Meloni, M. Di Stasi et al., “Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?” Hepatology, vol. 47, no. 1, pp. 82–89, 2008.

K. Yan, “Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors,” Eur J Radiol, vol. 67, no. 2, pp. 336–347, 2008.

Y.-S. Kim, H. K. Lim, H. Rhim et al., “Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors,” Journal of Hepatology, vol. 58, no. 1, pp. 89–97, 2013.

M. Morimoto, K. Numata, M. Kondou, A. Nozaki, S. Morita, and K. Tanaka, “Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: A randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization,” Cancer, vol. 116, no. 23, pp. 5452–5460, 2010.

M. Kobayashi, K. Ikeda, Y. Kawamura et al., “Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma - Direct ablative effects and a long-term outcome,” Liver International, vol. 27, no. 3, pp. 353–359, 2007.

V. Cartier, J. Boursier, J. Lebigot, F. Oberti, I. Fouchard-Hubert, and C. Aubé, “Radiofrequency ablation of hepatocellular carcinoma: Mono or multipolar?” Journal of Gastroenterology and Hepatology, vol. 31, no. 3, pp. 654–660, 2016.

S. Shiina, T. Teratani, S. Obi, K. Hamamura, Y. Koike, and M. Omata, “Nonsurgical treatment of hepatocellular carcinoma: From percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation,” Oncology, vol. 62, no. 1, pp. 64–68, 2002.

C. L. Brace, P. F. Laeseke, L. A. Sampson, T. M. Frey, D. W. Van Der Weide, and F. T. Lee Jr., “Microwave ablation with a single small-gauge triaxial antenna: In vivo porcine liver model,” Radiology, vol. 242, no. 2, pp. 435–440, 2007.

G. D. Dodd III, N. A. Dodd, A. C. Lanctot, and D. A. Glueck, “Effect of variation of portal venous blood flow on radiofrequency and microwave ablations in a blood-perfused bovine liver model,” Radiology, vol. 267, no. 1, pp. 129–136, 2013.

W. Fan, X. Li, L. Zhang, H. Jiang, and J. Zhang, “Comparison of microwave ablation and multipolar radiofrequency ablation in vivo using two internally cooled probes,” American Journal of Roentgenology, vol. 198, no. 1, pp. W46–W50, 2012.

M. G. Lubner, C. L. Brace, J. L. Hinshaw, and F. T. Lee Jr., “Microwave tumor ablation: mechanism of action, clinical results, and devices,” Journal of Vascular and Interventional Radiology, vol. 21, no. 8, pp. S192–S203, 2010.

R. T. Groeschl, C. H. C. Pilgrim, E. M. Hanna et al., “Microwave ablation for hepatic malignancies: A multiinstitutional analysis,” Annals of Surgery, vol. 259, no. 6, pp. 1195–1200, 2014.

Y. Liu, Y. Zheng, S. Li, B. Li, Y. Zhang, and Y. Yuan, “Percutaneous microwave ablation of larger hepatocellular carcinoma,” Clinical Radiology, vol. 68, no. 1, pp. 21–26, 2013.

E. W. Lee, C. Chen, V. E. Prieto, S. M. Dry, C. T. Loh, and S. T. Kee, “Advanced hepatic ablation technique for creating complete cell death: Irreversible electroporation,” Radiology, vol. 255, no. 2, pp. 426–433, 2010.

J. F. Edd, L. Horowitz, R. V. Davalos, L. M. Mir, and B. Rubinsky, “In vivo results of a new focal tissue ablation technique: irreversible electroporation,” IEEE Transactions on Biomedical Engineering, vol. 53, no. 7, pp. 1409–1415, 2006.

R. Cannon, S. Ellis, D. Hayes, G. Narayanan, and R. C. G. Martin II, “Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures,” Journal of Surgical Oncology, vol. 107, no. 5, pp. 544–549, 2013.

T. P. Kingham, A. M. Karkar, M. I. D'Angelica et al., “Ablation of perivascular hepatic malignant tumors with irreversible electroporation,” Journal of the American College of Surgeons, vol. 215, no. 3, pp. 379–387, 2012.

N. E. Hoffmann and J. C. Bischof, “The cryobiology of cryosurgical injury,” Urology, vol. 60, no. 2, pp. 40–49, 2002.

A. Orlacchio, G. Bazzocchi, D. Pastorelli et al., “Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: Initial experience,” CardioVascular and Interventional Radiology, vol. 31, no. 3, pp. 587–594, 2008.

Y.-Z. Huang, S.-C. Zhou, H. Zhou, and M. Tong, “Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: A meta-analysis,” Hepato-Gastroenterology, vol. 60, no. 125, pp. 1131–1135, 2013.

C. Wang, H. Wang, W. Yang et al., “Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma,” Hepatology, vol. 61, no. 5, pp. 1579–1590, 2015.

R. A. Lencioni, H.-P. Allgaier, D. Cioni et al., “Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection,” Radiology, vol. 228, no. 1, pp. 235–240, 2003.

S.-M. Lin, C.-J. Lin, C.-C. Lin, C.-W. Hsu, and Y.-C. Chen, “Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤4 cm,” Gastroenterology, vol. 127, no. 6, pp. 1714–1723, 2004.

S.-M. Lin, C.-J. Lin, C.-C. Lin, C.-W. Hsu, and Y.-C. Chen, “Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less,” Gut, vol. 54, no. 8, pp. 1151–1156, 2005.

F. Brunello, A. Veltri, P. Carucci et al., “Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial,” Scandinavian Journal of Gastroenterology, vol. 43, no. 6, pp. 727–735, 2008.

A. Giorgio, A. Di Sarno, G. De Stefano et al., “Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: An Italian randomized controlled trial,” Anticancer Reseach, vol. 31, no. 6, pp. 2291–2295, 2011.

T. Shibata, Y. Iimuro, Y. Yamamoto et al., “Small hepatocellular carcinoma: Comparison of radio-frequency ablation and percutaneous microwave coagulation therapy,” Radiology, vol. 223, no. 2, pp. 331–337, 2002.

K. Ohmoto, N. Yoshioka, Y. Tomiyama et al., “Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas,” Journal of Gastroenterology and Hepatology, vol. 24, no. 2, pp. 223–227, 2009.

T. J. Vogl, P. Farshid, N. N. N. Naguib et al., “Ablation therapy of hepatocellular carcinoma: a comparative study between radiofrequency and microwave ablation,” Abdominal Imaging, vol. 40, no. 6, pp. 1829–1837, 2015.

L. Zhang, N. Wang, Q. Shen, W. Cheng, and G.-J. Qian, “Therapeutic efficacy of percutaneous radiofrequency ablation versus microwave ablation for hepatocellular carcinoma,” PLoS ONE, vol. 8, no. 10, Article ID e76119, 2013.

M.-D. Lu, H.-X. Xu, X.-Y. Xie et al., “Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: A retrospective comparative study,” Journal of Gastroenterology, vol. 40, no. 11, pp. 1054–1060, 2005.

J. Ding, X. Jing, J. Liu et al., “Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma,” European Journal of Radiology, vol. 82, no. 9, pp. 1379–1384, 2013.

A. Abdelaziz, T. Elbaz, H. I. Shousha et al., “Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an egyptian multidisciplinary clinic experience,” Surgical Endoscopy, vol. 28, no. 12, pp. 3429–3434, 2014.

M. S. Chen et al., “A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma,” Ann Surg, vol. 243, no. 3, pp. 321–328, 2006.

K. Feng, J. Yan, X. Li et al., “A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma,” Journal of Hepatology, vol. 57, no. 4, pp. 794–802, 2012.

Y. Fang, W. Chen, X. Liang et al., “Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma,” Journal of Gastroenterology and Hepatology, vol. 29, no. 1, pp. 193–200, 2014.

J. Huang, Y. Zeng, H. Wu, Z. Chen, and Q. Lu, “A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection For HCC Conforming to the Milan Criteria,” Annals of Surgery, vol. 254, no. 5, p. 839, 2011.

H. Liu, Z. G. Wang, S. Y. Fu et al., “Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria,” British Journal of Surgery, vol. 103, no. 4, pp. 348–356, 2016.

S. N. Hong et al., “Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function,” J Clin Gastroenterol, vol. 39, no. 3, pp. 247–252, 2005.

K. Yamagiwa, K. Shiraki, K. Yamakado et al., “Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study,” Journal of Gastroenterology and Hepatology, vol. 23, no. 3, pp. 482–490, 2008.

K. Yamakado, A. Nakatsuka, H. Takaki et al., “Early-stage hepatocellular carcinoma: Radiofrequency ablation combined with chemoembolization versus hepatectomy,” Radiology, vol. 247, no. 1, pp. 260–266, 2008.

G.-A. Kim, J. H. Shim, M.-J. Kim et al., “Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas,” British Journal of Surgery, vol. 103, no. 1, pp. 126–135, 2016.

L. Jiang, L. Yan, T. Wen et al., “Comparison of Outcomes of Hepatic Resection and Radiofrequency Ablation for Hepatocellular Carcinoma Patients with Multifocal Tumors Meeting the Barcelona-Clinic Liver Cancer Stage A Classification,” Journal of the American College of Surgeons, vol. 221, no. 5, pp. 951–961, 2015.

T. W. Kang, J. M. Kim, H. Rhim et al., “Small hepatocellular carcinoma: Radiofrequency ablation versus nonanatomic resection - Propensity score analyses of long-term outcomes,” Radiology, vol. 275, no. 3, pp. 908–919, 2015.

H. Yang, J. Lee, D. H. Lee et al., “Small Single-Nodule Hepatocellular Carcinoma: Comparison of Transarterial Chemoembolization, Radiofrequency Ablation, and Hepatic Resection by Using Inverse Probability Weighting,” Radiology, vol. 271, no. 3, pp. 909–918, 2014.

A. Cucchetti, F. Piscaglia, M. Cescon et al., “An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma,” Digestive and Liver Disease, vol. 46, no. 3, pp. 257–263, 2014.

Z. Zhou and et al., “Liver resection and radiofrequency ablation of very early hepatocellular carcinoma cases (single nodule <2 cm): a single-center study,” Eur J Gastroenterol Hepatol, vol. 26, no. 3, pp. 339–344, 2014.

S. Tohme, D. A. Geller, J. S. Cardinal et al., “Radiofrequency ablation compared to resection in early-stage hepatocellular carcinoma,” HPB, vol. 15, no. 3, pp. 210–217, 2013.

T. Takayama, M. Makuuchi, and K. Hasegawa, “Single HCC smaller than 2 cm: Surgery or ablation? Surgeon's perspective,” Journal of Hepato-Biliary-Pancreatic Sciences, vol. 17, no. 4, pp. 422–424, 2010.

H. Hung, Y. Chiou, C. Hsia et al., “Survival Rates Are Comparable After Radiofrequency Ablation or Surgery in Patients With Small Hepatocellular Carcinomas,” Clinical Gastroenterology and Hepatology, vol. 9, no. 1, pp. 79–86, 2011.

R. Santambrogio, E. Opocher, M. Zuin et al., “Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and child-pugh class a liver cirrhosis,” Annals of Surgical Oncology, vol. 16, no. 12, pp. 3289–3298, 2009.

K.-M. Wong, M.-L. Yeh, S.-C. Chuang et al., “Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma,” Indian Journal of Gastroenterology, vol. 32, no. 4, pp. 253–257, 2013.

M. Vivarelli, A. Guglielmi, A. Ruzzenente et al., “Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver,” Annals of Surgery, vol. 240, no. 1, pp. 102–107, 2004.

A. Guglielmi, A. Ruzzenente, A. Valdegamberi et al., “Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis,” Journal of Gastrointestinal Surgery, vol. 12, no. 1, pp. 192–198, 2008.

I. Gory, M. Fink, S. Bell et al., “Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study,” Scandinavian Journal of Gastroenterology, vol. 50, no. 5, pp. 567–576, 2015.

K. Hasegawa, N. Kokudo, M. Makuuchi et al., “Corrigendum to: “Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey” [J Hepatol 2013;58:724–729],” Journal of Hepatology, vol. 59, no. 3, p. 641, 2013.

W. K. Yun, M. S. Choi, D. Choi et al., “Superior long-term outcomes after surgery in child-pugh class a patients with single small hepatocellular carcinoma compared to radiofrequency ablation,” Hepatology International, vol. 5, no. 2, pp. 722–729, 2011.

J. Desiderio, S. Trastulli, R. Pasquale et al., “Could radiofrequency ablation replace liver resection for small hepatocellular carcinoma in patients with compensated cirrhosis? A 5-year follow-up,” Langenbeck's Archives of Surgery, vol. 398, no. 1, pp. 55–62, 2013.

Y.-H. Lee, C.-Y. Hsu, C.-W. Chu et al., “Radiofrequency ablation is better than surgical resection in patients with hepatocellular carcinoma within the Milan criteria and preserved liver function: A retrospective study using propensity score analyses,” Journal of Clinical Gastroenterology, vol. 49, no. 3, pp. 242–249, 2015.

Z.-W. Peng, X.-J. Lin, Y.-J. Zhang et al., “Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: A retrospective comparative study,” Radiology, vol. 262, no. 3, pp. 1022–1033, 2012.

A. Cucchetti, F. Piscaglia, M. Cescon et al., “Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma,” Journal of Hepatology, vol. 59, no. 2, pp. 300–307, 2013.